Biomarkers to predict response to treatment in metastatic melanoma patients

Summary of the technology

This technology is a panel of genetic biomarkers that can predict or predict the response of patients with metastatic melanoma who carry BRAF mutations to treatment with BRAF and MEK inhibitors.
▪ Allow the development of a diagnostic kit or device.
▪ Thanks to the prediction of prognosis, patients with worse
prognosis can be followed more closely.
▪ This panel allows a further step towards personalized medicine, enabling more patient-focused and efficient clinical care.

Details of the Technology Offer

Melanoma is a tumor of great molecular complexity with a great variability of mutations that define the type of treatment.

Currently, the study of the presence or absence of mutations in the BRAF oncogene in this type of patients, mainly in those who present metastasis, is being fundamental, since it is present in between 40 and 50% of them.

Treatment with immune checkpoint inhibitors is the most widely used treatment for metastatic melanoma with BRAF mutations, for which specific therapies have been developed. These treatments produce large tumor regression responses and a high increase in the number of survivors and in the life expectancy of these patients, in those who respond. However, it was necessary to develop a strategy to predict or predict the response of these patients.

To this end, our researchers have developed a panel of genetic biomarkers that can predict or predict the response of patients with metastatic melanoma who carry BRAF mutations to treatment with BRAF and MEK inhibitors.

Intellectual property status

  • Patent already applied for
  • Patent application number :P202031326

Attached documents

Related Keywords

  • Medical Health related
  • Diagnostic
  • Molecular diagnosis
  • Clinical Medicine
  • Oncology

About IBIMA-Plataforma Bionand

IBIMA is a space for multidisciplinary research in biomedicine and nanomedicine that is centered around the Regional and Virgen de la Victoria University Hospitals in Malaga, together with Primary Care, the biotechnological groups of the University of Malaga and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND).

IBIMA-Plataforma Bionand

Never miss an update from IBIMA-Plataforma Bionand

Create your free account to connect with IBIMA-Plataforma Bionand and thousands of other innovative organizations and professionals worldwide

IBIMA-Plataforma Bionand

Send a request for information
to IBIMA-Plataforma Bionand

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support